Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients

Publisher： Karger

E-ISSN： 1423-0232|84|2|115-122

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.2, 2012-11, pp. : 115-122

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 350-354

Karger

Access to resources Recommend Favorite

Continuous Therapy with Sunitinib in Patients with Metastatic Renal Cell Carcinoma

By  

Oncology Research and Treatment, Vol. 31, Iss. 8-9, 2008-07 ,pp. : 485-485

Karger

Access to resources Recommend Favorite

Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles

By  

Oncology, Vol. 80, Iss. 5-6, 2011-08 ,pp. : 395-405

Karger

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 328-333

John Wiley & Sons Inc

Access to resources Recommend Favorite